[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fUe-1ypJLZML0U3eE1E9Oca_-tFsViVM0B00ebtXhpp0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":43,"rows":50},"University of Bologna",[4],154,false,21,4,239106,2,123,[14,17,20,22,24,26,29,31],{"name":15,"count":16},"Hypercholesterolemia",11,{"name":18,"count":19},"Low Back Pain",6,{"name":21,"count":9},"Atherosclerosis",{"name":23,"count":9},"Obesity",{"name":25,"count":9},"Chronic Myeloid Leukemia",{"name":27,"count":28},"Abdominal Aortic Aneurysm",3,{"name":30,"count":28},"Acute Coronary Syndrome",{"name":32,"count":28},"Inflammation",[34,39],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06086132","Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry","2026-12-31","Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy",{"nctId":40,"briefTitle":41,"date":37,"intervention":42},"NCT05188612","International Survey of Acute Coronavirus Syndromes-COVID-19","Observational",[44,45,46,47,48,49],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[51,75,95,124,142,169,187,213,239,257,286,304,322,346,372,390,415,443,461,479,519,544,573,591,609,627,659,677,695,720,747,765,783,807,831,854,875,899,923,947,972,996,1024],{"intervention":38,"totalTrials":52,"cells":53},1,{"EARLY_PHASE1":54,"PHASE1":57,"PHASE2":59,"PHASE3":61,"PHASE4":63,"NA":65},{"trials":55,"activeCount":56},[],0,{"trials":58,"activeCount":56},[],{"trials":60,"activeCount":56},[],{"trials":62,"activeCount":56},[],{"trials":64,"activeCount":56},[],{"trials":66,"activeCount":52,"soonestReadout":37},[67],{"nctId":35,"briefTitle":36,"status":68,"phases":69,"primaryCompletion":37,"completion":37,"start":70,"enrollment":71,"conditions":72,"interventions":74},"RECRUITING",[],"2025-05-01",10000,[73],"Cancer Related Cardiovascular Toxicity",[38],{"intervention":42,"totalTrials":52,"cells":76},{"EARLY_PHASE1":77,"PHASE1":79,"PHASE2":81,"PHASE3":83,"PHASE4":85,"NA":87},{"trials":78,"activeCount":56},[],{"trials":80,"activeCount":56},[],{"trials":82,"activeCount":56},[],{"trials":84,"activeCount":56},[],{"trials":86,"activeCount":56},[],{"trials":88,"activeCount":52,"soonestReadout":37},[89],{"nctId":40,"briefTitle":41,"status":68,"phases":90,"primaryCompletion":37,"completion":37,"start":91,"enrollment":71,"conditions":92,"interventions":94},[],"2021-12-01",[93],"COVID-19",[42],{"intervention":96,"totalTrials":52,"cells":97},"Diuretics plus human albumin",{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":122},{"trials":99,"activeCount":56},[],{"trials":101,"activeCount":56},[],{"trials":103,"activeCount":56},[],{"trials":105,"activeCount":56},[],{"trials":107,"activeCount":56},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":120},"NCT01288794","Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis","COMPLETED",[48],"2014-11","2016-05","2011-03",431,[118,119],"Liver Cirrhosis","Ascites",[96,121],"Diuretics",{"trials":123,"activeCount":56},[],{"intervention":121,"totalTrials":52,"cells":125},{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":140},{"trials":127,"activeCount":56},[],{"trials":129,"activeCount":56},[],{"trials":131,"activeCount":56},[],{"trials":133,"activeCount":56},[],{"trials":135,"activeCount":56},[136],{"nctId":109,"briefTitle":110,"status":111,"phases":137,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":138,"interventions":139},[48],[118,119],[96,121],{"trials":141,"activeCount":56},[],{"intervention":143,"totalTrials":52,"cells":144},"budesonide",{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":151,"PHASE4":153,"NA":167},{"trials":146,"activeCount":56},[],{"trials":148,"activeCount":56},[],{"trials":150,"activeCount":56},[],{"trials":152,"activeCount":56},[],{"trials":154,"activeCount":56},[155],{"nctId":156,"briefTitle":157,"status":111,"phases":158,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":165},"NCT00912171","Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome in Children",[48],"2010-04","2010-06","2009-01",45,[164],"Obstructive Sleep Apnea Syndrome",[143,166],"montelukast",{"trials":168,"activeCount":56},[],{"intervention":166,"totalTrials":52,"cells":170},{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":179,"NA":185},{"trials":172,"activeCount":56},[],{"trials":174,"activeCount":56},[],{"trials":176,"activeCount":56},[],{"trials":178,"activeCount":56},[],{"trials":180,"activeCount":56},[181],{"nctId":156,"briefTitle":157,"status":111,"phases":182,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":183,"interventions":184},[48],[164],[143,166],{"trials":186,"activeCount":56},[],{"intervention":188,"totalTrials":52,"cells":189},"Rituximab",{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":196,"PHASE4":198,"NA":211},{"trials":191,"activeCount":56},[],{"trials":193,"activeCount":56},[],{"trials":195,"activeCount":56},[],{"trials":197,"activeCount":56},[],{"trials":199,"activeCount":56},[200],{"nctId":201,"briefTitle":202,"status":203,"phases":204,"start":205,"enrollment":206,"conditions":207,"interventions":210},"NCT00797810","Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults","UNKNOWN",[48],"2006-12",25,[208,209],"Acute Lymphoblastic Leukemia","Non-Hodgkin's Lymphoma",[188],{"trials":212,"activeCount":56},[],{"intervention":214,"totalTrials":52,"cells":215},"Ertapenem",{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":224,"NA":237},{"trials":217,"activeCount":56},[],{"trials":219,"activeCount":56},[],{"trials":221,"activeCount":56},[],{"trials":223,"activeCount":56},[],{"trials":225,"activeCount":56},[226],{"nctId":227,"briefTitle":228,"status":111,"phases":229,"primaryCompletion":160,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":235},"NCT00630513","T.E.A. Study Three Days Ertapenem Versus Three Days Ampicillin- Sulbactam",[48],"2010-12","2008-01",142,[234],"Intra-Abdominal Infection",[214,236],"Ampicillin-Sulbactam",{"trials":238,"activeCount":56},[],{"intervention":236,"totalTrials":52,"cells":240},{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":247,"PHASE4":249,"NA":255},{"trials":242,"activeCount":56},[],{"trials":244,"activeCount":56},[],{"trials":246,"activeCount":56},[],{"trials":248,"activeCount":56},[],{"trials":250,"activeCount":56},[251],{"nctId":227,"briefTitle":228,"status":111,"phases":252,"primaryCompletion":160,"completion":230,"start":231,"enrollment":232,"conditions":253,"interventions":254},[48],[234],[214,236],{"trials":256,"activeCount":56},[],{"intervention":258,"totalTrials":52,"cells":259},"cyclosporine",{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":266,"PHASE4":268,"NA":284},{"trials":261,"activeCount":56},[],{"trials":263,"activeCount":56},[],{"trials":265,"activeCount":56},[],{"trials":267,"activeCount":56},[],{"trials":269,"activeCount":56},[270],{"nctId":271,"briefTitle":272,"status":273,"phases":274,"primaryCompletion":161,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":281},"NCT00420537","Shift to Everolimus (RAD) Kidney Sparing Study","TERMINATED",[48],"2009-03","2006-09",34,[279,280],"Kidney Dysfunction","Heart Transplantation",[258,258,282,283],"Mycophenolate mofetil","Everolimus",{"trials":285,"activeCount":56},[],{"intervention":282,"totalTrials":52,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":296,"NA":302},{"trials":289,"activeCount":56},[],{"trials":291,"activeCount":56},[],{"trials":293,"activeCount":56},[],{"trials":295,"activeCount":56},[],{"trials":297,"activeCount":56},[298],{"nctId":271,"briefTitle":272,"status":273,"phases":299,"primaryCompletion":161,"completion":275,"start":276,"enrollment":277,"conditions":300,"interventions":301},[48],[279,280],[258,258,282,283],{"trials":303,"activeCount":56},[],{"intervention":283,"totalTrials":52,"cells":305},{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":312,"PHASE4":314,"NA":320},{"trials":307,"activeCount":56},[],{"trials":309,"activeCount":56},[],{"trials":311,"activeCount":56},[],{"trials":313,"activeCount":56},[],{"trials":315,"activeCount":56},[316],{"nctId":271,"briefTitle":272,"status":273,"phases":317,"primaryCompletion":161,"completion":275,"start":276,"enrollment":277,"conditions":318,"interventions":319},[48],[279,280],[258,258,282,283],{"trials":321,"activeCount":56},[],{"intervention":323,"totalTrials":52,"cells":324},"fluvastatin",{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":344},{"trials":326,"activeCount":56},[],{"trials":328,"activeCount":56},[],{"trials":330,"activeCount":56},[],{"trials":332,"activeCount":56},[],{"trials":334,"activeCount":56},[335],{"nctId":336,"briefTitle":337,"status":203,"phases":338,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":343},"NCT00421005","Fluvastatin After Heart Transplantation",[48],"2008-11","2004-11",56,[280,15],[323],{"trials":345,"activeCount":56},[],{"intervention":347,"totalTrials":52,"cells":348},"tirofiban high-bolus dose regimen",{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":357,"NA":370},{"trials":350,"activeCount":56},[],{"trials":352,"activeCount":56},[],{"trials":354,"activeCount":56},[],{"trials":356,"activeCount":56},[],{"trials":358,"activeCount":56},[359],{"nctId":360,"briefTitle":361,"status":111,"phases":362,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":366,"interventions":368},"NCT00383136","FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab",[48],"2007-09","2003-06",692,[367],"Acute Myocardial Infarction",[347,369],"Abciximab",{"trials":371,"activeCount":56},[],{"intervention":369,"totalTrials":52,"cells":373},{"EARLY_PHASE1":374,"PHASE1":376,"PHASE2":378,"PHASE3":380,"PHASE4":382,"NA":388},{"trials":375,"activeCount":56},[],{"trials":377,"activeCount":56},[],{"trials":379,"activeCount":56},[],{"trials":381,"activeCount":56},[],{"trials":383,"activeCount":56},[384],{"nctId":360,"briefTitle":361,"status":111,"phases":385,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":386,"interventions":387},[48],[367],[347,369],{"trials":389,"activeCount":56},[],{"intervention":391,"totalTrials":52,"cells":392},"Gastrografin®: G",{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":399,"PHASE4":401,"NA":413},{"trials":394,"activeCount":56},[],{"trials":396,"activeCount":56},[],{"trials":398,"activeCount":56},[],{"trials":400,"activeCount":56},[],{"trials":402,"activeCount":56},[403],{"nctId":404,"briefTitle":405,"status":111,"phases":406,"completion":407,"start":408,"enrollment":409,"conditions":410,"interventions":412},"NCT00601809","(Gastrografin Use in Small Bowel Obstruction Caused by Adherences)",[48],"2006-11","2003-09",76,[411],"Adhesive Small Intestine Obstruction",[391],{"trials":414,"activeCount":56},[],{"intervention":416,"totalTrials":52,"cells":417},"NER1006",{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":424,"PHASE4":426,"NA":441},{"trials":419,"activeCount":56},[],{"trials":421,"activeCount":56},[],{"trials":423,"activeCount":56},[],{"trials":425,"activeCount":56},[],{"trials":427,"activeCount":56},[428],{"nctId":429,"briefTitle":430,"status":203,"phases":431,"primaryCompletion":432,"completion":433,"start":434,"enrollment":435,"conditions":436,"interventions":438},"NCT04708366","Colon Cleansing Efficacy With 1L vs. 2L vs. 4L-PEG for Colonoscopy Among Inpatients",[48],"2022-03-15","2022-05-15","2021-02-01",846,[437],"Colon Disease",[416,439,440],"MoviPrep","Macrogol 400",{"trials":442,"activeCount":56},[],{"intervention":439,"totalTrials":52,"cells":444},{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":451,"PHASE4":453,"NA":459},{"trials":446,"activeCount":56},[],{"trials":448,"activeCount":56},[],{"trials":450,"activeCount":56},[],{"trials":452,"activeCount":56},[],{"trials":454,"activeCount":56},[455],{"nctId":429,"briefTitle":430,"status":203,"phases":456,"primaryCompletion":432,"completion":433,"start":434,"enrollment":435,"conditions":457,"interventions":458},[48],[437],[416,439,440],{"trials":460,"activeCount":56},[],{"intervention":440,"totalTrials":52,"cells":462},{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":469,"PHASE4":471,"NA":477},{"trials":464,"activeCount":56},[],{"trials":466,"activeCount":56},[],{"trials":468,"activeCount":56},[],{"trials":470,"activeCount":56},[],{"trials":472,"activeCount":56},[473],{"nctId":429,"briefTitle":430,"status":203,"phases":474,"primaryCompletion":432,"completion":433,"start":434,"enrollment":435,"conditions":475,"interventions":476},[48],[437],[416,439,440],{"trials":478,"activeCount":56},[],{"intervention":480,"totalTrials":28,"cells":481},"STI571",{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":506,"PHASE4":515,"NA":517},{"trials":483,"activeCount":56},[],{"trials":485,"activeCount":56},[],{"trials":487,"activeCount":56},[488,496],{"nctId":489,"briefTitle":490,"status":111,"phases":491,"start":492,"enrollment":493,"conditions":494,"interventions":495},"NCT00511303","Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia",[46],"2000-08",200,[25],[480],{"nctId":497,"briefTitle":498,"status":203,"phases":499,"start":500,"conditions":501,"interventions":505},"NCT00276926","Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias",[46],"2003-03",[502,503,504],"Hypereosinophilic Syndrome","Chronic Eosinophilic Leukemia (CEL)","Myeloproliferative Disorders",[480],{"trials":507,"activeCount":56},[508],{"nctId":509,"briefTitle":510,"status":111,"phases":511,"start":512,"conditions":513,"interventions":514},"NCT00514488","Imatinib Standard Dose (400 mg\u002FDay) Versus Imatinib High Dose (800 mg\u002FDay)",[47],"2004-06",[25],[480],{"trials":516,"activeCount":56},[],{"trials":518,"activeCount":56},[],{"intervention":520,"totalTrials":52,"cells":521},"Ursodeoxycholic Acid",{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":528,"PHASE4":540,"NA":542},{"trials":523,"activeCount":56},[],{"trials":525,"activeCount":56},[],{"trials":527,"activeCount":56},[],{"trials":529,"activeCount":56},[530],{"nctId":531,"briefTitle":532,"status":533,"phases":534,"primaryCompletion":535,"completion":535,"start":536,"enrollment":56,"conditions":537,"interventions":539},"NCT01226823","Ursodeoxycholic Acid And Cholestasis Of Pregnancy","WITHDRAWN",[47],"2013-11","2010-11",[538],"Intrahepatic Cholestasis of Pregnancy",[520],{"trials":541,"activeCount":56},[],{"trials":543,"activeCount":56},[],{"intervention":545,"totalTrials":52,"cells":546},"Pre-emptive strategy with valganciclovir plus everolimus",{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":553,"PHASE4":569,"NA":571},{"trials":548,"activeCount":56},[],{"trials":550,"activeCount":56},[],{"trials":552,"activeCount":56},[],{"trials":554,"activeCount":56},[555],{"nctId":556,"briefTitle":557,"status":203,"phases":558,"primaryCompletion":559,"start":560,"enrollment":561,"conditions":562,"interventions":565},"NCT00966836","Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy",[47],"2012-04","2009-04",100,[280,563,564],"Cardiac Allograft Vasculopathy","Cytomegalovirus Infection",[545,566,567,568],"Prophylaxis with valganciclovir plus mycophenolate","Prophylaxis with valganciclovir plus everolimus","Pre-emptive mycophenolate",{"trials":570,"activeCount":56},[],{"trials":572,"activeCount":56},[],{"intervention":566,"totalTrials":52,"cells":574},{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":579,"PHASE3":581,"PHASE4":587,"NA":589},{"trials":576,"activeCount":56},[],{"trials":578,"activeCount":56},[],{"trials":580,"activeCount":56},[],{"trials":582,"activeCount":56},[583],{"nctId":556,"briefTitle":557,"status":203,"phases":584,"primaryCompletion":559,"start":560,"enrollment":561,"conditions":585,"interventions":586},[47],[280,563,564],[545,566,567,568],{"trials":588,"activeCount":56},[],{"trials":590,"activeCount":56},[],{"intervention":567,"totalTrials":52,"cells":592},{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":605,"NA":607},{"trials":594,"activeCount":56},[],{"trials":596,"activeCount":56},[],{"trials":598,"activeCount":56},[],{"trials":600,"activeCount":56},[601],{"nctId":556,"briefTitle":557,"status":203,"phases":602,"primaryCompletion":559,"start":560,"enrollment":561,"conditions":603,"interventions":604},[47],[280,563,564],[545,566,567,568],{"trials":606,"activeCount":56},[],{"trials":608,"activeCount":56},[],{"intervention":568,"totalTrials":52,"cells":610},{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":617,"PHASE4":623,"NA":625},{"trials":612,"activeCount":56},[],{"trials":614,"activeCount":56},[],{"trials":616,"activeCount":56},[],{"trials":618,"activeCount":56},[619],{"nctId":556,"briefTitle":557,"status":203,"phases":620,"primaryCompletion":559,"start":560,"enrollment":561,"conditions":621,"interventions":622},[47],[280,563,564],[545,566,567,568],{"trials":624,"activeCount":56},[],{"trials":626,"activeCount":56},[],{"intervention":628,"totalTrials":11,"cells":629},"Zevalin",{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":653,"PHASE4":655,"NA":657},{"trials":631,"activeCount":56},[],{"trials":633,"activeCount":56},[],{"trials":635,"activeCount":56},[636,645],{"nctId":637,"briefTitle":638,"status":111,"phases":639,"enrollment":640,"conditions":641,"interventions":643},"NCT00850512","Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy",[46],55,[642],"Diffuse Large B-Cell Lymphoma",[644,628],"CHOP21-R",{"nctId":646,"briefTitle":647,"status":111,"phases":648,"enrollment":640,"conditions":649,"interventions":651},"NCT00859001","Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy",[46],[650],"Follicular Lymphoma",[652,628],"FM+R",{"trials":654,"activeCount":56},[],{"trials":656,"activeCount":56},[],{"trials":658,"activeCount":56},[],{"intervention":644,"totalTrials":52,"cells":660},{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":671,"PHASE4":673,"NA":675},{"trials":662,"activeCount":56},[],{"trials":664,"activeCount":56},[],{"trials":666,"activeCount":56},[667],{"nctId":637,"briefTitle":638,"status":111,"phases":668,"enrollment":640,"conditions":669,"interventions":670},[46],[642],[644,628],{"trials":672,"activeCount":56},[],{"trials":674,"activeCount":56},[],{"trials":676,"activeCount":56},[],{"intervention":652,"totalTrials":52,"cells":678},{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":689,"PHASE4":691,"NA":693},{"trials":680,"activeCount":56},[],{"trials":682,"activeCount":56},[],{"trials":684,"activeCount":56},[685],{"nctId":646,"briefTitle":647,"status":111,"phases":686,"enrollment":640,"conditions":687,"interventions":688},[46],[650],[652,628],{"trials":690,"activeCount":56},[],{"trials":692,"activeCount":56},[],{"trials":694,"activeCount":56},[],{"intervention":696,"totalTrials":52,"cells":697},"Lenalidomide",{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":714,"PHASE4":716,"NA":718},{"trials":699,"activeCount":56},[],{"trials":701,"activeCount":56},[],{"trials":703,"activeCount":56},[704],{"nctId":705,"briefTitle":706,"status":273,"phases":707,"primaryCompletion":708,"completion":709,"start":339,"enrollment":710,"conditions":711,"interventions":713},"NCT01036399","Study of Lenalidomide (Revlimid) in Patients With Relapsed\u002FRefractory Peripheral T-cell Lymphoma (PTCL) Patients",[46],"2009-08","2011-08",9,[712],"Peripheral T-cell Lymphoma",[696],{"trials":715,"activeCount":56},[],{"trials":717,"activeCount":56},[],{"trials":719,"activeCount":56},[],{"intervention":721,"totalTrials":52,"cells":722},"Cabozantinib 20 MG",{"EARLY_PHASE1":723,"PHASE1":725,"PHASE2":727,"PHASE3":741,"PHASE4":743,"NA":745},{"trials":724,"activeCount":56},[],{"trials":726,"activeCount":56},[],{"trials":728,"activeCount":56},[729],{"nctId":730,"briefTitle":731,"status":203,"phases":732,"primaryCompletion":733,"completion":734,"start":735,"enrollment":206,"conditions":736,"interventions":738},"NCT04131543","Phase II Study With Cabozantinib in Patients With RET Positive NSCLC",[46],"2020-08-07","2022-08-07","2019-08-07",[737],"Non Small Cell Lung Cancer",[721,739,740],"Cabozantinib 40 MG","Cabozantinib 60 MG",{"trials":742,"activeCount":56},[],{"trials":744,"activeCount":56},[],{"trials":746,"activeCount":56},[],{"intervention":739,"totalTrials":52,"cells":748},{"EARLY_PHASE1":749,"PHASE1":751,"PHASE2":753,"PHASE3":759,"PHASE4":761,"NA":763},{"trials":750,"activeCount":56},[],{"trials":752,"activeCount":56},[],{"trials":754,"activeCount":56},[755],{"nctId":730,"briefTitle":731,"status":203,"phases":756,"primaryCompletion":733,"completion":734,"start":735,"enrollment":206,"conditions":757,"interventions":758},[46],[737],[721,739,740],{"trials":760,"activeCount":56},[],{"trials":762,"activeCount":56},[],{"trials":764,"activeCount":56},[],{"intervention":740,"totalTrials":52,"cells":766},{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":777,"PHASE4":779,"NA":781},{"trials":768,"activeCount":56},[],{"trials":770,"activeCount":56},[],{"trials":772,"activeCount":56},[773],{"nctId":730,"briefTitle":731,"status":203,"phases":774,"primaryCompletion":733,"completion":734,"start":735,"enrollment":206,"conditions":775,"interventions":776},[46],[737],[721,739,740],{"trials":778,"activeCount":56},[],{"trials":780,"activeCount":56},[],{"trials":782,"activeCount":56},[],{"intervention":784,"totalTrials":52,"cells":785},"Lenalidomide plus Rituximab",{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":801,"PHASE4":803,"NA":805},{"trials":787,"activeCount":56},[],{"trials":789,"activeCount":56},[],{"trials":791,"activeCount":56},[792],{"nctId":793,"briefTitle":794,"status":273,"phases":795,"primaryCompletion":796,"completion":797,"start":275,"enrollment":206,"conditions":798,"interventions":800},"NCT00968331","Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma (DLBCL)",[46],"2009-12","2011-12",[799],"Diffuse Large B-cell Lymphoma",[784],{"trials":802,"activeCount":56},[],{"trials":804,"activeCount":56},[],{"trials":806,"activeCount":56},[],{"intervention":808,"totalTrials":52,"cells":809},"Tipifarnib plus Bortezomib",{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":814,"PHASE3":825,"PHASE4":827,"NA":829},{"trials":811,"activeCount":56},[],{"trials":813,"activeCount":56},[],{"trials":815,"activeCount":56},[816],{"nctId":817,"briefTitle":818,"status":203,"phases":819,"start":820,"enrollment":821,"conditions":822,"interventions":824},"NCT00510939","Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia",[46],"2007-03",72,[823],"Acute Myeloid Leukemia",[808],{"trials":826,"activeCount":56},[],{"trials":828,"activeCount":56},[],{"trials":830,"activeCount":56},[],{"intervention":832,"totalTrials":52,"cells":833},"STI571 and PEG INTRON",{"EARLY_PHASE1":834,"PHASE1":836,"PHASE2":838,"PHASE3":848,"PHASE4":850,"NA":852},{"trials":835,"activeCount":56},[],{"trials":837,"activeCount":56},[],{"trials":839,"activeCount":56},[840],{"nctId":841,"briefTitle":842,"status":273,"phases":843,"start":844,"enrollment":845,"conditions":846,"interventions":847},"NCT00511121","Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)",[46],"2001-04",5,[25],[832],{"trials":849,"activeCount":56},[],{"trials":851,"activeCount":56},[],{"trials":853,"activeCount":56},[],{"intervention":855,"totalTrials":52,"cells":856},"Imatinib",{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":869,"PHASE4":871,"NA":873},{"trials":858,"activeCount":56},[],{"trials":860,"activeCount":56},[],{"trials":862,"activeCount":56},[863],{"nctId":864,"briefTitle":865,"status":111,"phases":866,"start":492,"conditions":867,"interventions":868},"NCT00514969","Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase",[46],[25],[855],{"trials":870,"activeCount":56},[],{"trials":872,"activeCount":56},[],{"trials":874,"activeCount":56},[],{"intervention":876,"totalTrials":52,"cells":877},"Imatinib Mesilate",{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":882,"PHASE3":893,"PHASE4":895,"NA":897},{"trials":879,"activeCount":56},[],{"trials":881,"activeCount":56},[],{"trials":883,"activeCount":56},[884],{"nctId":885,"briefTitle":886,"status":111,"phases":887,"completion":407,"start":888,"enrollment":889,"conditions":890,"interventions":892},"NCT00510926","Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase",[46],"2004-01",80,[891],"Myeloid Leukemia, Chronic, Chronic-Phase",[876],{"trials":894,"activeCount":56},[],{"trials":896,"activeCount":56},[],{"trials":898,"activeCount":56},[],{"intervention":900,"totalTrials":52,"cells":901},"Bortezomib",{"EARLY_PHASE1":902,"PHASE1":904,"PHASE2":906,"PHASE3":917,"PHASE4":919,"NA":921},{"trials":903,"activeCount":56},[],{"trials":905,"activeCount":56},[],{"trials":907,"activeCount":56},[908],{"nctId":909,"briefTitle":910,"status":111,"phases":911,"primaryCompletion":912,"completion":912,"start":913,"enrollment":28,"conditions":914,"interventions":916},"NCT00511069","Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia",[46],"2008-02","2006-07",[915],"Leukemia",[900],{"trials":918,"activeCount":56},[],{"trials":920,"activeCount":56},[],{"trials":922,"activeCount":56},[],{"intervention":924,"totalTrials":52,"cells":925},"doxorubicin liposomal",{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":941,"PHASE4":943,"NA":945},{"trials":927,"activeCount":56},[],{"trials":929,"activeCount":56},[],{"trials":931,"activeCount":56},[932],{"nctId":933,"briefTitle":934,"status":203,"phases":935,"primaryCompletion":936,"completion":936,"start":937,"enrollment":28,"conditions":938,"interventions":940},"NCT00801580","My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia",[46],"2010-09","2008-03",[939],"Lymphoid Leukemia",[924],{"trials":942,"activeCount":56},[],{"trials":944,"activeCount":56},[],{"trials":946,"activeCount":56},[],{"intervention":948,"totalTrials":52,"cells":949},"autologous highly purified CD133+ stem cells",{"EARLY_PHASE1":950,"PHASE1":952,"PHASE2":964,"PHASE3":966,"PHASE4":968,"NA":970},{"trials":951,"activeCount":56},[],{"trials":953,"activeCount":56},[954],{"nctId":955,"briefTitle":956,"status":203,"phases":957,"primaryCompletion":958,"completion":959,"start":960,"enrollment":961,"conditions":962,"interventions":963},"NCT01025622","Intrahepatic Reinfusion of CD133+ Stem Cells in Cirrhotic Patients",[45],"2011-06","2012-06","2009-10",12,[118],[948],{"trials":965,"activeCount":56},[],{"trials":967,"activeCount":56},[],{"trials":969,"activeCount":56},[],{"trials":971,"activeCount":56},[],{"intervention":973,"totalTrials":52,"cells":974},"NK cells",{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":988,"PHASE3":990,"PHASE4":992,"NA":994},{"trials":976,"activeCount":56},[],{"trials":978,"activeCount":56},[979],{"nctId":980,"briefTitle":981,"status":203,"phases":982,"primaryCompletion":796,"completion":796,"start":983,"enrollment":984,"conditions":985,"interventions":987},"NCT00799799","Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells",[45],"2005-10",15,[986],"Myeloblastic Leukemia",[973],{"trials":989,"activeCount":56},[],{"trials":991,"activeCount":56},[],{"trials":993,"activeCount":56},[],{"trials":995,"activeCount":56},[],{"intervention":997,"totalTrials":52,"cells":998},"COVID-19 vaccination",{"EARLY_PHASE1":999,"PHASE1":1001,"PHASE2":1003,"PHASE3":1005,"PHASE4":1007,"NA":1009},{"trials":1000,"activeCount":56},[],{"trials":1002,"activeCount":56},[],{"trials":1004,"activeCount":56},[],{"trials":1006,"activeCount":56},[],{"trials":1008,"activeCount":56},[],{"trials":1010,"activeCount":56},[1011],{"nctId":1012,"briefTitle":1013,"status":111,"phases":1014,"primaryCompletion":1015,"completion":1016,"start":1017,"enrollment":1018,"conditions":1019,"interventions":1023},"NCT05222139","Monitoring COVID-19 Vaccination Response in Fragile Populations",[],"2023-07-16","2024-11-30","2021-05-24",8894,[1020,1021,1022],"SARS CoV 2 Infection","Vaccination; Infection","Breakthrough Infection",[997],{"intervention":1025,"totalTrials":52,"cells":1026},"PPI",{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1031,"PHASE3":1033,"PHASE4":1035,"NA":1037},{"trials":1028,"activeCount":56},[],{"trials":1030,"activeCount":56},[],{"trials":1032,"activeCount":56},[],{"trials":1034,"activeCount":56},[],{"trials":1036,"activeCount":56},[],{"trials":1038,"activeCount":56},[1039],{"nctId":1040,"briefTitle":1041,"status":111,"phases":1042,"primaryCompletion":1043,"completion":1043,"start":1043,"enrollment":1044,"conditions":1045,"interventions":1049},"NCT07041060","Evaluation of the Efficacy and Safety of Eolo in Patients With NERD",[49],"2025-05-30",60,[1046,1047,1048],"Non-erosive Reflux Disease","Reflux Disease, Gastro-Esophageal","Nutraceutical",[1025]]